Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Crescent Biopharma (CBIO) Shares Outstanding (Diluted Average) (2016 - 2024)

Crescent Biopharma (CBIO) has disclosed Shares Outstanding (Diluted Average) for 9 consecutive years, with $64.5 million as the latest value for Q3 2024.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 2.35% to $64.5 million in Q3 2024 year-over-year; TTM through Sep 2024 was $64.5 million, a 2.35% increase, with the full-year FY2023 number at $63.3 million, up 20.58% from a year prior.
  • Shares Outstanding (Diluted Average) was $64.5 million for Q3 2024 at Crescent Biopharma, roughly flat from $64.5 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $64.5 million in Q1 2024 to a low of $45.7 million in Q4 2020.
  • A 5-year average of $56.8 million and a median of $52.5 million in 2022 define the central range for Shares Outstanding (Diluted Average).
  • Peak YoY movement for Shares Outstanding (Diluted Average): rose 23.17% in 2023, then rose 0.1% in 2024.
  • Crescent Biopharma's Shares Outstanding (Diluted Average) stood at $45.7 million in 2020, then grew by 12.54% to $51.5 million in 2021, then rose by 2.1% to $52.5 million in 2022, then grew by 20.58% to $63.3 million in 2023, then rose by 1.79% to $64.5 million in 2024.
  • Per Business Quant, the three most recent readings for CBIO's Shares Outstanding (Diluted Average) are $64.5 million (Q3 2024), $64.5 million (Q2 2024), and $64.5 million (Q1 2024).